공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 액체생검 시장 예측(2021-2028년)

Global Liquid Biopsy Market Forecast 2021-2028

리서치사 Inkwood Research
발행일 2021년 03월 상품 코드 995692
페이지 정보 영문 270 Pages
가격
US $ 2,500 ₩ 2,856,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,427,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,140,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 액체생검 시장 예측(2021-2028년) Global Liquid Biopsy Market Forecast 2021-2028
발행일 : 2021년 03월 페이지 정보 : 영문 270 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 액체생검 시장 규모는 2021-2028년의 예측 기간 중 18.91%의 CAGR로 성장할 것으로 예측되고 있습니다. 고령자에서 암 유병률의 상승, 진단 센터에 대한 소비자 수요의 변화, 액체생검의 비침습성, 조직/종양 불문 약제의 출현 및 액체생검 검사에 대한 환자의 선호도 등은 시장의 성장을 촉진하는 요인입니다.

세계의 액체생검 시장에 대해 조사했으며, 시장의 개요, 시장에 영향을 미치는 요인 분석, 각 부문·하위 부문·지역의 시장 예측 및 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 조사 범위·조사 방법

  • 조사 목적
  • 조사 범위
  • 조사 방법
  • 전제조건·제한사항

제2장 개요

  • 시장 규모·추산
  • 시장 개요

제3장 시장 역학

  • 시장의 정의
  • 주요 촉진요인
    • 정부 구상의 증가
    • 고령자에서 암증례의 발생률
    • 진단 센터 소비자의 수요 변화
    • 액체생검 검사의 비침습적 성질
    • 조직/종양 불문 약제의 출현
    • 액체생검 검사에 대한 환자의 선호도
    • 기술의 진보
  • 주요 억제요인
    • 표준 조작 절차(SOPS)에 관한 콘센서스의 결여
    • 불충분한 보수 구조
    • 테스트의 고비용
    • 상환 문제
    • 숙련 전문가의 부족

제4장 주요 분석

  • Porter의 산업 분석
  • 액체생검 시장에 대한 COVID-19의 영향
  • 주요 액체생검 구상
  • 규제 프레임워크
  • 시장 기회 매트릭스
  • 벤더 구도
  • 주요 투자 인사이트

제5장 시장 : 치료 용도별

  • 폐암
  • 유방암
  • 전립선암
  • 결장직장암
  • 흑색종
  • 기타 유형의 암
  • 비종양학 애플리케이션

제6장 시장 : 임상 애플리케이션별

  • 치료 모니터링
  • 예후·재발 모니터링
  • 치료법의 선택
  • 진단과 스크리닝

제7장 시장 : 바이오마커 유형별

  • 핵산
  • 단백질
  • 세포외소포
  • 세포

제8장 시장 : 분석 플랫폼별

  • NGS
  • 마이크로어레이
  • PCR
  • 프로테오믹스
  • 기타 분석 플랫폼

제9장 시장 : 분석 목적별

  • 조기 발견/스크리닝
  • 치료 가이던스
  • 모니터링
  • 진단

제10장 시장 : 제품별

  • 무세포 종양 DNA(CTDNA)
  • 순환종양세포(CTCS)
  • 무세포 DNA(CFDNA)
  • 세포외소포 및 기타

제11장 시장 : 최종사용자별

  • 진료소 랩
  • 병원
  • 임상 진단 연구소

제12장 지역 분석

  • 북미
    • 시장 규모·추산
    • 주요 성장 이네이블러
    • 주요 과제
    • 주요 기업
    • 각국 분석
  • 유럽
  • 아시아태평양
  • 기타 지역

제13장 경쟁 구도

  • 주요 전략적 개발
    • 합병과 인수
    • 제품 발매와 개발
    • 파트너십, 계약/계약 및 협업
    • 사업 확대/승인/발표
  • 기업 개요
    • ADAPTIVE BIOTECHNOLOGIES
    • AGILENT TECHNOLOGIES INC
    • ANGLE PLC
    • BECTON, DICKINSON AND COMPANY(BD)
    • BIOCEPT INC
    • BIO-RAD LABORATORIES INC
    • F. HOFFMANN-LA ROCHE
    • FOUNDATION MEDICINE
    • GRAIL
    • GUARDANT HEALTH INC
    • ILLUMINA INC
    • MDXHEALTH SA
    • MENARINI-SILICON BIOSYSTEMS
    • MYRIAD GENETICS INC
    • NATERA
    • PERSONAL GENOME DIAGNOSTICS
    • QIAGEN NV
    • THERMO FISHER SCIENTIFIC INC
KSA 21.03.25

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - LIQUID BIOPSY
  • TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
  • TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
  • TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
  • TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 23: LEADING PLAYERS OPERATING IN NORTH AMERICA LIQUID BIOPSY MARKET
  • TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 25: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 26: LEADING PLAYERS OPERATING IN EUROPE LIQUID BIOPSY MARKET
  • TABLE 27: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 28: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 29: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET
  • TABLE 30: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 31: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 32: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET
  • TABLE 33: LIST OF MERGERS & ACQUISITIONS
  • TABLE 34: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 35: LIST OF PARTNERSHIPS AND AGREEMENTS
  • TABLE 36: LIST OF BUSINESS EXPANSIONS AND DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, IN 2020
  • FIGURE 6: GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2021-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, IN 2020
  • FIGURE 14: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2021-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2021-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2021-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2021-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, IN 2020
  • FIGURE 19: GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACID, 2021-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL LIQUID BIOPSY MARKET, BY PROTEIN, 2021-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2021-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2021-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, IN 2020
  • FIGURE 24: GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2021-2028 (IN $ MILLION)
  • FIGURE 25: GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2021-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2021-2028 (IN $ MILLION)
  • FIGURE 27: GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2021-2028 (IN $ MILLION)
  • FIGURE 28: GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORMS, 2021-2028 (IN $ MILLION)
  • FIGURE 29: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, IN 2020
  • FIGURE 30: GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2021-2028 (IN $ MILLION)
  • FIGURE 31: GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2021-2028 (IN $ MILLION)
  • FIGURE 32: GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2021-2028 (IN $ MILLION)
  • FIGURE 33: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2021-2028 (IN $ MILLION)
  • FIGURE 34: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, IN 2020
  • FIGURE 35: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2021-2028 (IN $ MILLION)
  • FIGURE 36: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2021-2028 (IN $ MILLION)
  • FIGURE 37: GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2021-2028 (IN $ MILLION)
  • FIGURE 38: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2021-2028 (IN $ MILLION)
  • FIGURE 39: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, IN 2020
  • FIGURE 40: GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS' OFFICE LABORATORIES, 2021-2028 (IN $ MILLION)
  • FIGURE 41: GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)
  • FIGURE 42: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2021-2028 (IN $ MILLION)
  • FIGURE 43: NORTH AMERICA LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 44: UNITED STATES LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 45: CANADA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 46: EUROPE LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 47: UNITED KINGDOM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 48: FRANCE LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 49: GERMANY LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 50: ITALY LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 51: RUSSIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 52: BELGIUM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 53: POLAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 54: REST OF EUROPE LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 55: ASIA-PACIFIC LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 56: JAPAN LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 57: CHINA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 58: INDIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 59: SOUTH KOREA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 60: AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 61: THAILAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 62: INDONESIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 63: VIETNAM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 64: REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 65: REST OF WORLD LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 66: LATIN AMERICA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 67: MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

KEY FINDINGS

The global liquid biopsy market is projected to grow with a CAGR of 18.91%, over the forecasted years of 2021 to 2028. The increasing prevalence of cancer in the older populace, the shifting consumer demand for diagnostic centers, the non-invasive nature of liquid biopsy testing, the emergence of tissue/tumor-agnostic drugs, and patients' preference for liquid biopsy testing, are among the chief forces driving the market growth.

MARKET INSIGHTS

A liquid biopsy entails a non-invasive method, that helps monitor and determine cancer and other diseases. In order to perform a liquid biopsy, blood or other fluids, including, urine is collected, sequenced, and analyzed by the use of next-generation sequencing (NGS) systems and assays. Tissue biopsy, an invasive procedure, is now being replaced by liquid biopsy, owing to the latter's efficiency.

Continually transitioning consumer demands have generated a shift in diagnostic testing, from commercial laboratories and hospitals, closer to the patients' home. As a result, the change has considerably minimized the overall cost of testing. The majority of healthcare services being delivered at homes, across several countries, are mainly for urban areas, with a reduced focus on rural areas. However, developing countries have a high proportion of people living in rural areas with few diagnostic centers, and low accessibility. Such regions also observe a high rate of cancer deaths, accredited to the lack of disease awareness, thereby leading to the ignorance of treatment and diagnosis.

REGIONAL INSIGHTS

The global liquid biopsy market growth is assessed through the evaluation of North America, Europe, the Asia-Pacific, and the rest of the world. The Asia-Pacific is set to be the leading region over the forecast period, owing to factors such as, the increasing need for liquid biopsy products, the surging incidence of cancer, mainly due to low awareness and delayed detection, and the initiatives undertaken by the government.

COMPETITIVE INSIGHTS

Since the global liquid biopsy market is still developing and emerging, customers often prefer trying popular products, as it is convenient to switch from one product to another. However, with this aspect, the customers' loyalty is jeopardized. Hence, industrial rivalry is considered to be medium to high.

Some of the leading companies operating in the market are: Becton, Dickinson, and Company (BD), Agilent Technologies Inc, Qiagen NV, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. RISING GOVERNMENT INITIATIVES
    • 3.2.2. INCIDENCE OF CANCER CASES IN OLDER POPULACE
    • 3.2.3. SHIFTING DEMAND OF CONSUMERS FOR DIAGNOSTIC CENTERS
    • 3.2.4. NON-INVASIVE NATURE OF LIQUID BIOPSY TESTING
    • 3.2.5. EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
    • 3.2.6. PATIENTS' PREFERENCE FOR LIQUID BIOPSY TESTING
    • 3.2.7. TECHNOLOGICAL ADVANCEMENTS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
    • 3.3.2. POOR COMPENSATION STRUCTURES
    • 3.3.3. HIGH COST OF THE TEST
    • 3.3.4. REIMBURSEMENT ISSUES
    • 3.3.5. DEARTH OF SKILLED PROFESSIONALS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRIES
    • 4.1.2. THREAT OF SUBSTITUTIONS
    • 4.1.3. BUYERS POWER
    • 4.1.4. SUPPLIERS POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON LIQUID BIOPSY MARKET
  • 4.3. KEY LIQUID BIOPSY INITIATIVES
  • 4.4. REGULATORY FRAMEWORK
  • 4.5. OPPORTUNITY MATRIX
  • 4.6. VENDOR LANDSCAPE
  • 4.7. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTIC APPLICATION

  • 5.1. LUNG CANCER
  • 5.2. BREAST CANCER
  • 5.3. PROSTATE CANCER
  • 5.4. COLORECTAL CANCER
  • 5.5. MELANOMA CANCER
  • 5.6. OTHER TYPES OF CANCER
  • 5.7. NON-ONCOLOGY APPLICATION

6. MARKET BY CLINICAL APPLICATION

  • 6.1. TREATMENT MONITORING
  • 6.2. PROGNOSIS AND REOCCURRENCE MONITORING
  • 6.3. TREATMENT SELECTION
  • 6.4. DIAGNOSIS AND SCREENING

7. MARKET BY BIOMARKER TYPE

  • 7.1. NUCLEIC ACID
  • 7.2. PROTEIN
  • 7.3. EXTRACELLULAR VESICLES
  • 7.4. CELLS

8. MARKET BY ANALYSIS PLATFORM

  • 8.1. NGS
  • 8.2. MICROARRAY
  • 8.3. PCR
  • 8.4. PROTEOMICS
  • 8.5. OTHER ANALYSIS PLATFORMS

9. MARKET BY ANALYSIS PURPOSE

  • 9.1. EARLY DETECTION/SCREENING
  • 9.2. THERAPY GUIDANCE
  • 9.3. MONITORING
  • 9.4. DIAGNOSIS

10. MARKET BY PRODUCT

  • 10.1. CIRCULATING TUMOR DNA (CTDNA)
  • 10.2. CIRCULATING TUMOR CELLS (CTCS)
  • 10.3. CELL-FREE DNA (CFDNA)
  • 10.4. EXTRACELLULAR VESICLES AND OTHERS

11. MARKET BY END-USER

  • 11.1. PHYSICIANS' OFFICE LABORATORIES
  • 11.2. HOSPITALS
  • 11.3. CLINICAL DIAGNOSTIC LABORATORIES

12. GEOGRAPHICAL ANALYSIS

  • 12.1. NORTH AMERICA
    • 12.1.1. MARKET SIZE & ESTIMATES
    • 12.1.2. KEY GROWTH ENABLERS
    • 12.1.3. KEY CHALLENGES
    • 12.1.4. KEY PLAYERS
    • 12.1.5. COUNTRY ANALYSIS
      • 12.1.5.1. UNITED STATES
      • 12.1.5.2. CANADA
  • 12.2. EUROPE
    • 12.2.1. MARKET SIZE & ESTIMATES
    • 12.2.2. KEY GROWTH ENABLERS
    • 12.2.3. KEY CHALLENGES
    • 12.2.4. KEY PLAYERS
    • 12.2.5. COUNTRY ANALYSIS
      • 12.2.5.1. UNITED KINGDOM
      • 12.2.5.2. FRANCE
      • 12.2.5.3. GERMANY
      • 12.2.5.4. ITALY
      • 12.2.5.5. RUSSIA
      • 12.2.5.6. BELGIUM
      • 12.2.5.7. POLAND
      • 12.2.5.8. REST OF EUROPE
  • 12.3. ASIA-PACIFIC
    • 12.3.1. MARKET SIZE & ESTIMATES
    • 12.3.2. KEY GROWTH ENABLERS
    • 12.3.3. KEY CHALLENGES
    • 12.3.4. KEY PLAYERS
    • 12.3.5. COUNTRY ANALYSIS
      • 12.3.5.1. JAPAN
      • 12.3.5.2. CHINA
      • 12.3.5.3. INDIA
      • 12.3.5.4. SOUTH KOREA
      • 12.3.5.5. AUSTRALIA & NEW ZEALAND
      • 12.3.5.6. THAILAND
      • 12.3.5.7. INDONESIA
      • 12.3.5.8. VIETNAM
      • 12.3.5.9. REST OF ASIA-PACIFIC
  • 12.4. REST OF WORLD
    • 12.4.1. MARKET SIZE & ESTIMATES
    • 12.4.2. KEY GROWTH ENABLERS
    • 12.4.3. KEY CHALLENGES
    • 12.4.4. KEY PLAYERS
    • 12.4.5. REGIONAL ANALYSIS
      • 12.4.5.1. LATIN AMERICA
      • 12.4.5.2. MIDDLE EAST & AFRICA

13. COMPETITIVE LANDSCAPE

  • 13.1. KEY STRATEGIC DEVELOPMENTS
    • 13.1.1. MERGERS & ACQUISITIONS
    • 13.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 13.1.3. PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
    • 13.1.4. BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS
  • 13.2. COMPANY PROFILES
    • 13.2.1. ADAPTIVE BIOTECHNOLOGIES
    • 13.2.2. AGILENT TECHNOLOGIES INC
    • 13.2.3. ANGLE PLC
    • 13.2.4. BECTON, DICKINSON AND COMPANY (BD)
    • 13.2.5. BIOCEPT INC
    • 13.2.6. BIO-RAD LABORATORIES INC
    • 13.2.7. F. HOFFMANN-LA ROCHE
    • 13.2.8. FOUNDATION MEDICINE
    • 13.2.9. GRAIL
    • 13.2.10. GUARDANT HEALTH INC
    • 13.2.11. ILLUMINA INC
    • 13.2.12. MDXHEALTH SA
    • 13.2.13. MENARINI-SILICON BIOSYSTEMS
    • 13.2.14. MYRIAD GENETICS INC
    • 13.2.15. NATERA
    • 13.2.16. PERSONAL GENOME DIAGNOSTICS
    • 13.2.17. QIAGEN NV
    • 13.2.18. THERMO FISHER SCIENTIFIC INC
Back to Top
전화 문의
F A Q